Combination R-BAC Good Against Mantle Cell Lymphoma

Results of a recently published Phase II study by Italian researchers indicate that combination therapy with cytarabine, bendamustine and rituximab can deliver strong response-related outcomes against mantle cell lymphoma.

This combination, also known by the acronym R-BAC, was tested in 40 patients with confirmed mantle cell lymphoma, all of whom were at least 65 years old. Half of the patients were treatment naïve, while the other half had relapsed or refractory MCL following a single regimen of immunochemotherapy.

Lymphoma Treatment Center

Insurance Accepted.
Innovative Lymphoma Treatments.
Call 415-343-6162 Today

The primary outcome measure for this study was overall response rate (ORR), which was measure by PET scan. Secondary endpoints were progression-free survival, overall survival and safety. The safety of the dosage was performed in stage one of the study to determine the maximum tolerated dose of cytarabine. Participants then received rituximab on the first day, bendamustine on days two and three, and cytarabine on days two and four every 28 days for between four and six cycles.

Almost all of the participants were staged as having either stage III or stage IV mantle cell lymphoma.

Response Rates

Results indicated that the response rate among the treatment naïve cohort was 100 percent, and this group had a 95 percent rate of progression free survival.

Among the previously treated group the overall response rate was 80 percent, and the progression free survival rate was 70 percent.

The researchers concluded:

On the basis of its remarkable activity, as well as stem-cell mobilizing potential in the first-line setting, R-BAC could be a useful option in the preintensification phase for younger patients with MCL, in whom achieving complete response before transplantation can elicit long-lasting remissions.

Source: Journal of Clinical Oncology

Lymphoma Treatment Center

Insurance Accepted.
Innovative Lymphoma Treatments.
Call 415-343-6162 Today

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...